Abstract
Cancer genetics is increasingly becoming central in the course of patients’ care. Genetic testing for pathogenic variants in ovarian cancer (OC) is becoming widely available and represents a cornerstone for cancer risk assessment, prediction of prognosis, and targeted treatments. The introduction of novel technologies for sequencing has enabled large-scale multigene panel genomic testing. In this chapter, the current genetic variants and genetic testing guidelines for OC are reviewed. We also discussed potential applications of next-generation sequencing in understanding OC genetics and its impact on patients’ outcomes according to the latest research findings. We finally depict the potential of single-cell sequencing in understanding OC heterogeneity based on recent proof-of-concept studies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ahmed AA et al (2010) Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 221(1):49–56
Alexandrova E et al (2020) An overview of candidate therapeutic target genes in ovarian cancer. Cancers 12(6):1470
Alsop K, Fereday S, Meldrum C, de Fazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30(21):2654–2663. https://doi.org/10.1200/JCO.2011.39.8545
American Cancer Society (2020) Key statistics for ovarian cancer. Accessed 12/2020
Amin N, Chaabouni N, George A (2020) Genetic testing for epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol 65:125–138. https://doi.org/10.1016/j.bpobgyn.2020.01.005
Angeli D, Salvi S, Tedaldi G (2020) Genetic predisposition to breast and ovarian cancers: how many and which genes to test? Int J Mol Sci 21(3):1128
Antony E et al (2009) Srs2 disassembles Rad51 filaments by a protein-protein interaction triggering ATP turnover and dissociation of Rad51 from DNA. Mol Cell 35(1):105–115
Arts-de Jong M et al (2016) Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: a systematic review. Eur J Cancer 61:137–145
Ashworth A (2008) Drug resistance caused by reversion mutation. Cancer Res 68(24):10021–10023. https://doi.org/10.1158/0008-5472.CAN-08-2287
Au-Yeung G et al (2017) Selective targeting of cyclin E1-amplified high-grade serous ovarian Cancer by cyclin-dependent kinase 2 and AKT inhibition. Clin Cancer Res 23(7):1862–1874
Bagger FO, Probst V (2020) Single cell sequencing in cancer diagnostics. Adv Exp Med Biol 1255:175–193. https://doi.org/10.1007/978-981-15-4494-1_15
Balasubramaniam S, Beaver JA, Horton S et al (2017) FDA approval summary: Rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer. Clin Cancer Res 23(23):7165–7170. https://doi.org/10.1158/1078-0432.CCR-17-1337
Balmana J, Domchek SM (2015) BRIP1 as an ovarian cancer susceptibility gene: ready for the clinic? J Natl Cancer Inst 107(11):djv262
Barbosa A et al (2020) Gene panel tumor testing in ovarian cancer patients significantly increases the yield of clinically actionable germline variants beyond BRCA1/BRCA2. Cancers 12(10):2834
Beggs AD et al (2010) Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut 59(7):975–986
Bogdanova NV et al (2019) A splice site variant of CDK12 and breast cancer in three Eurasian populations. Front Oncol 9:493
Bonadona V, Bonaïti B, Olschwang S, Grandjouan S, Huiart L, Longy M, Guimbaud R, Buecher B, Bignon YJ, Caron O, Colas C, Noguès C, Lejeune-Dumoulin S, Olivier-Faivre L, Polycarpe-Osaer F, Nguyen TD, Desseigne F, Saurin JC, Berthet P, Leroux D, Duffour J, Manouvrier S, Frébourg T, Sobol H, Lasset C, Bonaïti-Pellié C, French Cancer Genetics Network (2011) Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in lynch syndrome. JAMA 305(22):2304–2310. https://doi.org/10.1001/jama.2011.743
Boussios S, Karihtala P, Moschetta M, Abson C, Karathanasi A, Zakynthinakis-Kyriakou N, Ryan JE, Sheriff M, Rassy E, Pavlidis N (2020) Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. Investig New Drugs 38(1):181–193. https://doi.org/10.1007/s10637-019-00867-4
Bowtell DD (2010) The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 10(11):803–808. https://doi.org/10.1038/nrc2946
Bowtell DD et al (2015) Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer 15(11):668–679
Bryant H, Schultz N, Thomas H et al (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 434:913–917. https://doi.org/10.1038/nature03443
Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474(7353):609–615. https://doi.org/10.1038/nature10166. Erratum in: Nature. 2012; 490 (7419): 298
Carethers JM, Stoffel EM (2015) Lynch syndrome and lynch syndrome mimics: the growing complex landscape of hereditary colon cancer. World J Gastroenterol 21(31):9253–9261
Carracedo A, Pandolfi PP (2008) The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 27(41):5527–5541
Carter NJ, Marshall ML, Susswein LR, Zorn KK, Hiraki S, Arvai KJ, Torene RI, McGill AK, Yackowski L, Murphy PD, Xu Z, Solomon BD, Klein RT, Hruska KS (2018) Germline pathogenic variants identified in women with ovarian tumors. Gynecol Oncol 151(3):481–488. https://doi.org/10.1016/j.ygyno.2018.09.030
Caumanns JJ et al (2018) ARID1A mutant ovarian clear cell carcinoma: a clear target for synthetic lethal strategies. Biochim Biophys Acta Rev Cancer 1870(2):176–184
Chan AM et al (2020) Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma. J Pathol Clin Res 6(4):252–262
Chen YJ, Chen CM, Twu NF, Yen MS, Lai CR, Wu HH, Wang PH, Yuan CC (2009) Overexpression of Aurora B is associated with poor prognosis in epithelial ovarian cancer patients. Virchows Arch 455(5):431–440. https://doi.org/10.1007/s00428-009-0838-3
Chen P, Hsu WH, Han J, Xia Y, DePinho RA (2021) Cancer stemness meets immunity: from mechanism to therapy. Cell Rep 34(1):108597. https://doi.org/10.1016/j.celrep.2020.108597
Chien J et al (2015) TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer. Nucleic Acids Res 43(14):6945–6958
Chou J et al (2020) Transcription-associated cyclin-dependent kinases as targets and biomarkers for cancer therapy. Cancer Discov 10(3):351–370
Christie EL, Bowtell DDL (2017) Acquired chemotherapy resistance in ovarian cancer. Ann Oncol 28(suppl_8):viii13–viii15. https://doi.org/10.1093/annonc/mdx446
Chui MH, Momeni Boroujeni A, Mandelker D, Ladanyi M, Soslow RA (2020) Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma. Mod Pathol 34:490–501. https://doi.org/10.1038/s41379-020-00648-y
Coleman RL, Oza AM, Lorusso D et al (2017) Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390(10106):1949–1961. https://doi.org/10.1016/S0140-6736(17)32440-6
Cunningham JM, Cicek MS, Larson NB, Davila J, Wang C, Larson MC, Song H, Dicks EM, Harrington P, Wick M, Winterhoff BJ, Hamidi H, Konecny GE, Chien J, Bibikova M, Fan JB, Kalli KR, Lindor NM, Fridley BL, Pharoah PP, Goode EL (2014) Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status. Sci Rep 4:4026. https://doi.org/10.1038/srep04026
da Costa A et al (2019) Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes. BMC Cancer 19(1):422
da Cunha Colombo Bonadio RR, Fogace RN, Miranda VC, MDPE D (2018) Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management. Clinics (Sao Paulo) 73(suppl 1):e450s. https://doi.org/10.6061/clinics/2018/e450s
Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS (2011) Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle 10(8):1192–1199. https://doi.org/10.4161/cc.10.8.15273
Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146(6):904–917. https://doi.org/10.1016/j.cell.2011.08.017
Donawho CK, Luo Y, Luo Y et al (2007) ABT-888, an orally active poly (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13(9):2728–2737. https://doi.org/10.1158/1078-0432.CCR-06-3039
Du ZH, Bi FF, Wang L, Yang Q (2018) Next-generation sequencing unravels extensive genetic alteration in recurrent ovarian cancer and unique genetic changes in drug-resistant recurrent ovarian cancer. Mol Genet Genomic Med 6(4):638–647. https://doi.org/10.1002/mgg3.414
Dziadkowiec KN et al (2016) PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting. Prz Menopauzalny 15(4):215–219
El Bairi K, Azzam F, Amrani M (2020a) The arrival of next-generation sequencing: an overview of current technologies. In: El Bairi K (ed) Illuminating colorectal cancer genomics by next-generation sequencing. Springer, Cham. https://doi.org/10.1007/978-3-030-53821-7_3
El Bairi K, Trapani D, Amrani M (2020b) The revolution of liquid biopsy and single-cell sequencing in the management of colorectal cancer. In: El Bairi K (ed) Illuminating colorectal cancer genomics by next-generation sequencing. Springer, Cham. https://doi.org/10.1007/978-3-030-53821-7_6
Ellison G, Huang S, Carr H, Wallace A, Ahdesmaki M, Bhaskar S, Mills J (2015) A reliable method for the detection of BRCA1 and BRCA2 mutations in fixed tumour tissue utilising multiplex PCR-based targeted next generation sequencing. BMC Clin Pathol 15:5. https://doi.org/10.1186/s12907-015-0004-6
Endris V, Stenzinger A, Pfarr N et al (2016) NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial. Virchows Arch 468(6):697–705. https://doi.org/10.1007/s00428-016-1919-8
Engel C, Loeffler M, Steinke V, Rahner N, Holinski-Feder E, Dietmaier W, Schackert HK, Goergens H, von Knebel Doeberitz M, Goecke TO, Schmiegel W, Buettner R, Moeslein G, Letteboer TG, GĂłmez GarcĂa E, Hes FJ, Hoogerbrugge N, Menko FH, van Os TA, Sijmons RH, Wagner A, Kluijt I, Propping P, Vasen HF (2012) Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol 30(35):4409–4415. https://doi.org/10.1200/JCO.2012.43.2278
Erickson BK et al (2014) Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer. Obstet Gynecol 124(5):881–885
Eskander RN, Tewari KS (2014) PARP inhibition and synthetic lethality in ovarian cancer. Expert Rev Clin Pharmacol 7(5):613–622
Etemadmoghadam D et al (2013) Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc Natl Acad Sci U S A 110(48):19489–19494
Faraoni I, Graziani G (2018) Role of BRCA mutations in cancer treatment with poly (ADP-ribose) polymerase (PARP) inhibitors. Cancers 10(12):487
Färkkilä A, RodrĂguez A, Oikkonen J, Gulhan DC, Nguyen H, DomĂnguez J, Ramos S, Mills CE, Perez-Villatoro F, Lazaro JB, Zhou J, Clairmont CS, Moreau LA, Park PJ, Sorger PK, Hautaniemi S, Frias S, D'Andrea AD (2021) Heterogeneity and clonal evolution of acquired PARP inhibitor resistance in TP53- and BRCA1-deficient cells. Cancer Res 81(10):2774–2787. canres.2912.2020. https://doi.org/10.1158/0008-5472.CAN-20-2912
Faubert B et al (2014) Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1alpha. Proc Natl Acad Sci U S A 111(7):2554–2559
Fleury H et al (2019) Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence. Nat Commun 10(1):2556
Frey MK, Pothuri B (2017) Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature. Gynecol Oncol Res Pract 4:4
Geistlinger L, Oh S, Ramos M, Schiffer L, LaRue RS, Henzler CM, Munro SA, Daughters C, Nelson AC, Winterhoff BJ, Chang Z, Talukdar S, Shetty M, Mullany SA, Morgan M, Parmigiani G, Birrer MJ, Qin LX, Riester M, Starr TK, Waldron L (2020) Multiomic analysis of subtype evolution and heterogeneity in high-grade serous ovarian carcinoma. Cancer Res 80(20):4335–4345. https://doi.org/10.1158/0008-5472.CAN-20-0521
George SH et al (2016) Loss of LKB1 and p53 synergizes to alter fallopian tube epithelial phenotype and high-grade serous tumorigenesis. Oncogene 35(1):59–68
Germano G, Amirouchene-Angelozzi N, Rospo G, Bardelli A (2018) The clinical impact of the genomic landscape of mismatch repair-deficient cancers. Cancer Discov 8(12):1518–1528. https://doi.org/10.1158/2159-8290.CD-18-0150
Giannopoulou L, Kasimir-Bauer S, Lianidou ES (2018) Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA. Clin Chem Lab Med 56(2):186–197. https://doi.org/10.1515/cclm-2017-0019
Giri VN, Hyatt C, Gomella LG (2019) Germline testing for men with prostate cancer: navigating an expanding New World of genetic evaluation for precision therapy and precision management. J Clin Oncol 37(17):1455–1459
Gorodetska I, Kozeretska I, Dubrovska A (2019) BRCA genes: the role in genome stability, cancer stemness and therapy resistance. J Cancer 10(9):2109–2127
Gorringe KL, Campbell IG (2009) Large-scale genomic analysis of ovarian carcinomas. Mol Oncol 3(2):157–164. https://doi.org/10.1016/j.molonc.2008.12.005
Gorski JW, Ueland FR, Kolesar JM (2020) CCNE1 amplification as a predictive biomarker of chemotherapy resistance in epithelial ovarian cancer. Diagnostics (Basel) 10(5):279
Guillotin D, Martin SA (2014) Exploiting DNA mismatch repair deficiency as a therapeutic strategy. Exp Cell Res 329(1):110–115
Hahnen E, Baumann KH, Heimbach A et al (2016) Prevalence of somatic mutations in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1 study). J Clin Oncol 34(15_suppl):5544–5544. https://doi.org/10.1200/JCO.2016.34.15_suppl.5544
Hampel H et al (2015) A practice guideline from the American College of Medical Genetics and Genomics and the National Society of genetic counselors: referral indications for cancer predisposition assessment. Genet Med 17(1):70–87
Harter P, Hauke J, Heitz F et al (2017) Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). PLoS One 12(10):e0186043. https://doi.org/10.1371/journal.pone.0186043
Helder-Woolderink JM et al (2016) Ovarian cancer in lynch syndrome; a systematic review. Eur J Cancer 55:65–73
Helleday T (2011) The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol 5(4):387–393
Hemminki A et al (1998) A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391(6663):184–187
Hodgkinson K, Forrest LA, Vuong N, Garson K, Djordjevic B, Vanderhyden BC (2018) GREB1 is an estrogen receptor-regulated tumour promoter that is frequently expressed in ovarian cancer. Oncogene 37(44):5873–5886. https://doi.org/10.1038/s41388-018-0377-y
Howitt BE et al (2017) Clear cell ovarian cancers with microsatellite instability: a unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression. Onco Targets Ther 6(2):e1277308
Hu Z, Artibani M, Alsaadi A, Wietek N, Morotti M, Shi T, Zhong Z, Santana Gonzalez L, El-Sahhar S, Karami Nejad Ranjbar M, Mallett G, Feng Y, Masuda K, Zheng Y, Chong K, Damato S, Dhar S, Campo L, Garruto Campanile R, Soleymani Majd H, Rai V, Maldonado-Perez D, Jones S, Cerundolo V, Sauka-Spengler T, Yau C, Ahmed AA (2020) The repertoire of serous ovarian cancer non-genetic heterogeneity revealed by single-cell sequencing of normal fallopian tube epithelial cells. Cancer Cell 37(2):226–242.e7. https://doi.org/10.1016/j.ccell.2020.01.003
Izar B, Tirosh I, Stover EH, Wakiro I, Cuoco MS, Alter I, Rodman C, Leeson R, Su MJ, Shah P, Iwanicki M, Walker SR, Kanodia A, Melms JC, Mei S, Lin JR, Porter CBM, Slyper M, Waldman J, Jerby-Arnon L, Ashenberg O, Brinker TJ, Mills C, Rogava M, Vigneau S, Sorger PK, Garraway LA, Konstantinopoulos PA, Liu JF, Matulonis U, Johnson BE, Rozenblatt-Rosen O, Rotem A, Regev A (2020) A single-cell landscape of high-grade serous ovarian cancer. Nat Med 26(8):1271–1279. https://doi.org/10.1038/s41591-020-0926-0
Jones S, Wang TL, IeM S, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N (2010) Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330(6001):228–231. https://doi.org/10.1126/science.1196333
Kalkat M, De Melo J, Hickman KA, Lourenco C, Redel C, Resetca D, Tamachi A, Tu WB, Penn LZ (2017) MYC deregulation in primary human cancers. Genes (Basel) 8(6):151. https://doi.org/10.3390/genes8060151
Kanakkanthara A et al (2019) BRCA1 deficiency upregulates NNMT, which reprograms metabolism and sensitizes ovarian cancer cells to mitochondrial metabolic targeting agents. Cancer Res 79(23):5920–5929
Kawahara N et al (2017) Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer. Biomed Rep 7(5):391–399
Kobayashi H et al (2018) Conceptual frameworks of synthetic lethality in clear cell carcinoma of the ovary. Biomed Rep 9(2):112–118
Konecny GE, Wang C, Hamidi H, Winterhoff B, Kalli KR, Dering J, Ginther C, Chen HW, Dowdy S, Cliby W, Gostout B, Podratz KC, Keeney G, Wang HJ, Hartmann LC, Slamon DJ, Goode EL (2014) Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst 106(10):dju 249. https://doi.org/10.1093/jnci/dju249
Konstantinopoulos PA et al (2019) Phase II study of Avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. J Clin Oncol 37(30):2786–2794
Konstantinopoulos PA et al (2020) Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J Clin Oncol 38(11):1222–1245
Koshiyama M, Matsumura N, Konishi I (2014) Recent concepts of ovarian carcinogenesis: type I and type II. Biomed Res Int 2014:934261. https://doi.org/10.1155/2014/934261
Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso P, Patel MR, Domchek SM, Balmaña J, Drew Y, Chen LM, Safra T, Montes A, Giordano H, Maloney L, Goble S, Isaacson J, Xiao J, Borrow J, Rolfe L, Shapira-Frommer R (2017) A phase I-II study of the oral PARP inhibitor Rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors. Clin Cancer Res 23(15):4095–4106. https://doi.org/10.1158/1078-0432.CCR-16-2796
Kristeleit RS, Oaknin A, Ray-Coquard I, Leary A, Balmaña J, Drew Y, Oza AM, Shapira-Frommer R, Domchek SM, Cameron T, Maloney L, Goble S, Lorusso D, Ledermann JA, McNeish IA (2019) Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety. Int J Gynecol Cancer 29(9):1396–1404. https://doi.org/10.1136/ijgc-2019-000623
Kuchenbaecker KB et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416
Kuhn E et al (2012) TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions. J Pathol 226(3):421–426
Kuhn E et al (2016) CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma. Mod Pathol 29(10):1254–1261
Kurian AW et al (2019) Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients. J Clin Oncol 37(15):1305–1315
Kurman RJ, Shih IM (2016) The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol 186(4):733–747. https://doi.org/10.1016/j.ajpath.2015.11.011
Labidi-Galy SI, Olivier T, Rodrigues M, Ferraioli D, Derbel O, Bodmer A, Petignat P, Rak B, Chopin N, Tredan O, Heudel PE, Stuckelberger S, Meeus P, Meraldi P, Viassolo V, Ayme A, Chappuis PO, Stern MH, Houdayer C, Stoppa-Lyonnet D, Buisson A, Golmard L, Bonadona V, Ray-Coquard I (2018) Location of mutation in BRCA2 gene and survival in patients with ovarian cancer. Clin Cancer Res 24(2):326–333. https://doi.org/10.1158/1078-0432.CCR-17-2136
Lassmann S, Shen Y, Jütting U, Wiehle P, Walch A, Gitsch G, Hasenburg A, Werner M (2007) Predictive value of Aurora-a/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy. Clin Cancer Res 13(14):4083–4091. https://doi.org/10.1158/1078-0432.CCR-06-2775
Laviolette LA, Hodgkinson KM, Minhas N, Perez-Iratxeta C, Vanderhyden BC (2014) 17β-estradiol upregulates GREB1 and accelerates ovarian tumor progression in vivo. Int J Cancer 135(5):1072–1084. https://doi.org/10.1002/ijc.28741
Lawson DA, Kessenbrock K, Davis RT, Pervolarakis N, Werb Z (2018) Tumour heterogeneity and metastasis at single-cell resolution. Nat Cell Biol 20(12):1349–1360. https://doi.org/10.1038/s41556-018-0236-7
Ledermann JA (2016) PARP inhibitors in ovarian cancer. Ann Oncol 27(Suppl 1):i40–i44. https://doi.org/10.1093/annonc/mdw094
Ledermann JA, Drew Y, Kristeleit RS (2016) Homologous recombination deficiency and ovarian cancer. Eur J Cancer 60:49–58
Lheureux S, Tinker A, Clarke B et al (2018) A clinical and molecular phase II trial of Oral ENMD-2076 in ovarian clear cell carcinoma (OCCC): a study of the Princess Margaret phase II consortium. Clin Cancer Res 24(24):6168–6174. https://doi.org/10.1158/1078-0432.CCR-18-1244
Li GM (2008) Mechanisms and functions of DNA mismatch repair. Cell Res 18(1):85–98
Li R et al (2018) Two novel STK11 missense mutations induce phosphorylation of S6K and promote cell proliferation in Peutz-Jeghers syndrome. Oncol Lett 15(1):717–726
Li C, Bonazzoli E, Bellone S et al (2019) Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. Proc Natl Acad Sci U S A 116(2):619–624. https://doi.org/10.1073/pnas.1814027116. Epub 2018 Dec 24. Erratum in: Proc Natl Acad Sci U S A. 2019; 116 (12): 5829
Lim W et al (2004) Relative frequency and morphology of cancers in STK11 mutation carriers. Gastroenterology 126(7):1788–1794
Lord CJ, Ashworth A (2017) PARP inhibitors: synthetic lethality in the clinic. Science (New York, NY) 355(6330):1152–1158
Loveday C, Turnbull C, Ramsay E et al (2011) Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 43(9):879–882. https://doi.org/10.1038/ng.893
Loveday C et al (2012) Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet 44(5):475–476. author reply 476
Mafficini A, Simbolo M, Parisi A, Rusev B, Luchini C, Cataldo I, Piazzola E, Sperandio N, Turri G, Franchi M, Tortora G, Bovo C, Lawlor RT, Scarpa A (2016) BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing. Oncotarget 7(2):1076–1083. https://doi.org/10.18632/oncotarget.6834
Manchana T, Phoolcharoen N, Tantbirojn P (2019) BRCA mutation in high grade epithelial ovarian cancers. Gynecol Oncol Rep 29:102–105
Mandilaras V, Garg S, Cabanero M, Tan Q, Pastrello C, Burnier J, Karakasis K, Wang L, Dhani NC, Butler MO, Bedard PL, Siu LL, Clarke B, Shaw PA, Stockley T, Jurisica I, Oza AM, Lheureux S (2019) TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses. Int J Gynecol Cancer 29(2):346–352. ijgc-2018-000087. https://doi.org/10.1136/ijgc-2018-000087
Martins FC et al (2014) Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier. Genome Biol 15(12):526
Maru Y, Tanaka N, Ohira M, Itami M, Hippo Y, Nagase H (2017) Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis. Gynecol Oncol 144(2):377–383. https://doi.org/10.1016/j.ygyno.2016.11.045
Marzagalli M, Fontana F, Raimondi M, Limonta P (2021) Cancer stem cells-key players in tumor relapse. Cancers (Basel) 13(3):E376. https://doi.org/10.3390/cancers13030376
McConechy MK et al (2015) Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. Gynecol Oncol 137(2):306–310
Mirza MR et al (2016) Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375(22):2154–2164
Moller P et al (2017) Cancer incidence and survival in lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective lynch syndrome database. Gut 66(3):464–472
Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-MartĂn A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P (2018) Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379(26):2495–2505. https://doi.org/10.1056/NEJMoa1810858
Moyer VA (2014) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 160(4):271–281
Moyer CL et al (2020) Rare BRIP1 missense alleles confer risk for ovarian and breast cancer. Cancer Res 80(4):857–867
Mylavarapu S, Das A, Roy M (2018) Role of BRCA mutations in the modulation of response to platinum therapy. Front Oncol 8:16
Nakamura K et al (2014) Features of ovarian cancer in lynch syndrome (review). Mol Clin Oncol 2(6):909–916
NCCN Guiedelines (2019) National Comprehensive Cancer Network: ovarian cancer including fallopian tube cancer and primary peritoneal cancer, version 1. Available from https://www.nccn.org/physician_gls/pdf/ovarian.pdf
Nielsen FC, van Overeem HT, Sørensen CS (2016) Hereditary breast and ovarian cancer: new genes in confined pathways. Nat Rev Cancer 16(9):599–612. https://doi.org/10.1038/nrc.2016.72
Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Yi Q, Burger RA, Chan JK, Davidson SA, Mannel RS, DiSilvestro PA, Lankes HA, Ramirez NC, King MC, Swisher EM, Birrer MJ (2016a) Inherited mutations in women with ovarian carcinoma. JAMA Oncol 2(4):482–490. https://doi.org/10.1001/jamaoncol.2015.5495
Norquist BS, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner SI et al (2016b) Mutations in homologous recombination genes and response to treatment in GOG 218: an NRG oncology study. Gynecol Oncol 141:2. https://doi.org/10.1016/j.ygyno.2016.04.033
Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Burger RA, Tewari KS, Backes F, Mannel RS, Glaser G, Bailey C, Rubin S, Soper J, Lankes HA, Ramirez NC, King MC, Birrer MJ, Swisher EM (2018) Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: an NRG oncology/gynecologic oncology group study. Clin Cancer Res 24(4):777–783. https://doi.org/10.1158/1078-0432.CCR-17-1327
Oh BY, Shin HT, Yun JW, Kim KT, Kim J, Bae JS, Cho YB, Lee WY, Yun SH, Park YA, Park YH, Im YH, Lee J, Joung JG, Kim HC, Park WY (2019) Intratumor heterogeneity inferred from targeted deep sequencing as a prognostic indicator. Sci Rep 9(1):4542. https://doi.org/10.1038/s41598-019-41098-0
Paculova H et al (2017) BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors. Tumour Biol 39(10):1010428317727479. https://doi.org/10.1177/1010428317727479
Paracchini L et al (2020) Detection of TP53 clonal variants in Papanicolaou test samples collected up to 6 years prior to high-grade serous epithelial ovarian cancer diagnosis. JAMA Netw Open 3(7):e207566
Patch AM et al (2015) Whole-genome characterization of chemoresistant ovarian cancer. Nature 521(7553):489–494
Patni R (2019) Screening for ovarian cancer: an update. J Midlife Health 10(1):3–5
Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, Thornton A, Norquist BM, Casadei S, Nord AS, Agnew KJ, Pritchard CC, Scroggins S, Garcia RL, King MC, Swisher EM (2014) Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 20(3):764–775. https://doi.org/10.1158/1078-0432.CCR-13-2287
Pérez-Fidalgo JA, Gambardella V, Pineda B, Burgues O, Piñero O, Cervantes A (2020) Aurora kinases in ovarian cancer. ESMO Open 5(5):e000718. https://doi.org/10.1136/esmoopen-2020-000718
Petersen S et al (2020) CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes. Gynecol Oncol 157(2):405–410
Pino MS et al (2009) Deficient DNA mismatch repair is common in lynch syndrome-associated colorectal adenomas. J Mol Diagn 11(3):238–247
Prakash R et al (2015) Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb Perspect Biol 7(4):a016600
Rauh-Hain JA et al (2011) Ovarian cancer screening and early detection in the general population. Rev Obstet Gynecol 4(1):15–21
Reyes-González JM, Armaiz-Peña GN, Mangala LS, Valiyeva F, Ivan C, Pradeep S, EchevarrĂa-Vargas IM, Rivera-Reyes A, Sood AK, Vivas-MejĂa PE (2015) Targeting c-MYC in platinum-resistant ovarian cancer. Mol Cancer Ther 14(10):2260–2269. https://doi.org/10.1158/1535-7163.MCT-14-0801
Roh MH et al (2010) High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. Mod Pathol 23(10):1316–1324
Ross JS, Ali SM, Wang K, Palmer G, Yelensky R, Lipson D, Miller VA, Zajchowski D, Shawver LK, Stephens PJ (2013) Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies. Gynecol Oncol 130(3):554–559. https://doi.org/10.1016/j.ygyno.2013.06.019
Roy R, Chun J, Powell SN (2011) BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 12(1):68–78. https://doi.org/10.1038/nrc3181
Ruan J et al (2018) Quantitative assessment of aberrant P16(INK4a) methylation in ovarian cancer: a meta-analysis based on literature and TCGA datasets. Cancer Manag Res 10:3033–3046
Sallum LF et al (2018) WT1, p53 and p16 expression in the diagnosis of low- and high-grade serous ovarian carcinomas and their relation to prognosis. Oncotarget 9(22):15818–15827
Saotome K, Chiyoda T, Aimono E, Nakamura K, Tanishima S, Nohara S, Okada C, Hayashi H, Kuroda Y, Nomura H, Susumu N, Iwata T, Yamagami W, Kataoka F, Nishihara H, Aoki D (2020) Clinical implications of next-generation sequencing-based panel tests for malignant ovarian tumors. Cancer Med 9(20):7407–7417. https://doi.org/10.1002/cam4.3383
Shih AJ, Menzin A, Whyte J, Lovecchio J, Liew A, Khalili H, Bhuiya T, Gregersen PK, Lee AT (2018) Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq. PLoS One 13(11):e0206785. https://doi.org/10.1371/journal.pone.0206785. Erratum in: PLoS One. 2018 Dec 4; 13 (12): e0208778
Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7–30
Sokol ES et al (2019) Pan-Cancer analysis of CDK12 loss-of-function alterations and their association with the focal tandem-duplicator phenotype. Oncologist 24(12):1526–1533
Soletormos G et al (2016) Clinical use of Cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European group on tumor markers. Int J Gynecol Cancer 26(1):43–51
Song H, Dicks E, Ramus SJ et al (2015) Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population. J Clin Oncol 33(26):2901–2907. https://doi.org/10.1200/JCO.2015.61.2408
Soong TR et al (2019) The fallopian tube, "precursor escape" and narrowing the knowledge gap to the origins of high-grade serous carcinoma. Gynecol Oncol 152(2):426–433
Stoffel EM, Carethers JM (2020) Current approaches to germline cancer genetic testing. Annu Rev Med 71:85–102. https://doi.org/10.1146/annurev-med-052318-101009
Sud A, Kinnersley B, Houlston RS (2017) Genome-wide association studies of cancer: current insights and future perspectives. Nat Rev Cancer 17(11):692–704
Sun C, Chan F, Briassouli P, Linardopoulos S (2007) Aurora kinase inhibition downregulates NF-kappaB and sensitises tumour cells to chemotherapeutic agents. Biochem Biophys Res Commun 352(1):220–225. https://doi.org/10.1016/j.bbrc.2006.11.004
Sun H, Wang H, Wang X, Aoki Y, Wang X, Yang Y, Cheng X, Wang Z, Wang X (2020) Aurora-A/SOX8/FOXK1 signaling axis promotes chemoresistance via suppression of cell senescence and induction of glucose metabolism in ovarian cancer organoids and cells. Theranostics 10(15):6928–6945. https://doi.org/10.7150/thno.43811
Suszynska M, Ratajska M, Kozlowski P (2020) BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases. J Ovarian Res 13(1):50
Suvà ML, Tirosh I (2019) Single-cell RNA sequencing in cancer: lessons learned and emerging challenges. Mol Cell 75(1):7–12. https://doi.org/10.1016/j.molcel.2019.05.003
Swisher EM, Lin KK, Oza AM et al (2017) Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 18(1):75–87. https://doi.org/10.1016/S1470-2045(16)30559-9
Syngal S et al (2015) ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 110(2):223–262. quiz 263
Terada KY, Ahn HJ, Kessel B (2016) Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial. J Gynecol Oncol 27(3):e25. https://doi.org/10.3802/jgo.2016.27.e25
Topatana W et al (2020) Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation. J Hematol Oncol 13(1):118
Turk AA, Wisinski KB (2018) PARP inhibitors in breast cancer: bringing synthetic lethality to the bedside. Cancer 124(12):2498–2506
Vanderstichele A, Busschaert P, Olbrecht S, Lambrechts D, Vergote I (2017) Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer. Eur J Cancer 86:5–14. https://doi.org/10.1016/j.ejca.2017.08.029
Vang R et al (2016) Molecular alterations of TP53 are a defining feature of ovarian high-grade serous carcinoma: a rereview of cases lacking TP53 mutations in the cancer genome atlas ovarian study. Int J Gynecol Pathol 35(1):48–55
Verhaak RG, Tamayo P, Yang JY et al (2013) Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 123(1):517–525. https://doi.org/10.1172/JCI65833
Vitale SR, Groenendijk FH, van Marion R, Beaufort CM, Helmijr JC, Dubbink HJ, Dinjens WNM, Ewing-Graham PC, Smolders R, van Doorn HC, Boere IA, Berns EMJJ, Helleman J, Jansen MPHM (2020) TP53 mutations in serum circulating cell-free tumor DNA as longitudinal biomarker for high-grade serous ovarian cancer. Biomol Ther 10(3):415. https://doi.org/10.3390/biom10030415
Vuong NH, Cook DP, Forrest LA, Carter LE, Robineau-Charette P, Kofsky JM, Hodgkinson KM, Vanderhyden BC (2018) Single-cell RNA-sequencing reveals transcriptional dynamics of estrogen-induced dysplasia in the ovarian surface epithelium. PLoS Genet 14(11):e1007788. https://doi.org/10.1371/journal.pgen.1007788
Walsh T et al (2011) Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A 108(44):18032–18037
Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J (2000) BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 14(8):927–939
Wang H et al (2017) Expression of the tumor suppressor gene p16, and lymph node metastasis in patients with ovarian cancer. Oncol Lett 14(4):4689–4693
Weber-Lassalle N et al (2018) BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. Breast Cancer Res 20(1):7
Weren RD, Mensenkamp AR, Simons M, Eijkelenboom A, Sie AS, Ouchene H, van Asseldonk M, Gomez-Garcia EB, Blok MJ, de Hullu JA, Nelen MR, Hoischen A, Bulten J, Tops BB, Hoogerbrugge N, Ligtenberg MJ (2017) Novel BRCA1 and BRCA2 tumor test as basis for treatment decisions and referral for genetic counselling of patients with ovarian carcinomas. Hum Mutat 38:226–235. https://doi.org/10.1002/humu.23137
Wiegand KC, Shah SP, Al-Agha OM et al (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363(16):1532–1543. https://doi.org/10.1056/NEJMoa1008433
Winterhoff BJ, Maile M, Mitra AK, Sebe A, Bazzaro M, Geller MA, Abrahante JE, Klein M, Hellweg R, Mullany SA, Beckman K, Daniel J, Starr TK (2017) Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells. Gynecol Oncol 144(3):598–606. https://doi.org/10.1016/j.ygyno.2017.01.015. Erratum in: Gynecol Oncol. 2018 Oct; 151(1): 182–186
Winterhoff B, Talukdar S, Chang Z, Wang J, Starr TK (2019) Single-cell sequencing in ovarian cancer: a new frontier in precision medicine. Curr Opin Obstet Gynecol 31(1):49–55. https://doi.org/10.1097/GCO.0000000000000516
Xu X et al (2013) LKB1 controls human bronchial epithelial morphogenesis through p114RhoGEF-dependent RhoA activation. Mol Cell Biol 33(14):2671–2682
Yang H, He L, Kruk P et al (2006) Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer 119:2304–2312. https://doi.org/10.1002/ijc.22154
Yates MS, Timms K, Daniels MS, Oakley HD, Munsell MF, Lanchbury JS et al (2017) Evaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes. J Clin Oncol 35(15 Suppl):5511. https://doi.org/10.1200/JCO.2017.35.15_suppl.5511
Zhang L, Luo M, Yang H, Zhu S, Cheng X, Qing C (2019) Next-generation sequencing-based genomic profiling analysis reveals novel mutations for clinical diagnosis in Chinese primary epithelial ovarian cancer patients. J Ovarian Res 12(1):19. https://doi.org/10.1186/s13048-019-0494-4
Zhao RX, Xu ZX (2014) Targeting the LKB1 tumor suppressor. Curr Drug Targets 15(1):32–52
Zhao Q, Yang J, Li L, Cao D, Yu M, Shen K, BGI Group (2017) Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing. J Gynecol Oncol 28(4):e39. https://doi.org/10.3802/jgo.2017.28.e39
Zhao C, Li S, Zhao M, Zhu H, Zhu X (2018) Prognostic values of DNA mismatch repair genes in ovarian cancer patients treated with platinum-based chemotherapy. Arch Gynecol Obstet 297(1):153–159. https://doi.org/10.1007/s00404-017-4563-x
Zhu H et al (2020) Harnessing DNA replication stress for novel cancer therapy. Genes (Basel) 11(9):990
Zoppoli G et al (2012) CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute. Oncogene 31(4):403–418
Authors’ Contribution
AG and NS wrote Sect. 7.2. AT and KE wrote Sects. 7.3 and 7.4, respectively. KE coordinated the development of the chapter idea and shared a preliminary content discussion. The final draft was reviewed and approved by all the authors. The contents of the chapter reflect the authors’ perspectives and not of their institutions of affiliation.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive licence to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Ghoneum, A., Tazzite, A., El Bairi, K., Said, N. (2021). Cutting-Edge Technologies for Ovarian Cancer: An Overview of the Impact of Genetic Testing, Next-Generation Sequencing, and Single-Cell Analysis. In: El Bairi, K. (eds) Ovarian Cancer Biomarkers. Springer, Singapore. https://doi.org/10.1007/978-981-16-1873-4_7
Download citation
DOI: https://doi.org/10.1007/978-981-16-1873-4_7
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-16-1872-7
Online ISBN: 978-981-16-1873-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)